The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Abstract
BACKGROUND: The prevalence of osteoporosis is increasing in the United States. PURPOSE: To evaluate low bone mass and osteoporosis treatments to prevent fractures. DATA SOURCES: Ovid MEDLINE ALL, Ovid Evidence Based Medicine Reviews: Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov from 2014 through February 2022. STUDY SELECTION: ≥1000) for harms. DATA EXTRACTION: Abstracted by 1 reviewer and verified by a second. Independent, dual assessments of risk of bias and certainty of evidence (CoE). DATA SYNTHESIS: We included 34 RCTs (in 100 publications) and 36 observational studies. Bisphosphonates and denosumab reduced hip, clinical and radiographic vertebral, and other clinical fractures in postmenopausal females with osteoporosis (moderate to high CoE). Bisphosphonates for 36 months or more may increase the risk for atypical femoral fractures (AFFs) and osteonecrosis of the jaw (ONJ), but the absolute risks were low. Abaloparatide and teriparatide reduced clinical and radiographic vertebral fractures but increased the risk for withdrawals due to adverse events (WAEs; moderate to high CoE). Raloxifene and bazedoxifene for 36 months or more reduced radiographic vertebral but not clinical fractures (low to moderate CoE). Abaloparatide, teriparatide, and sequential romosozumab, then alendronate, may be more effective than bisphosphonates in reducing clinical fractures for 17 to 24 months in older postmenopausal females at very high fracture risk (low to moderate CoE). Bisphosphonates may reduce clinical fractures in older females with low bone mass (low CoE) and radiographic vertebral fractures in males with osteoporosis (low to moderate CoE). LIMITATION: Few studies examined participants with low bone mass, males, or Black-identifying persons, sequential therapy, or treatment beyond 3 years. CONCLUSION: Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis. Abaloparatide and teriparatide increased WAEs; longer duration bisphosphonate use may increase AFF and ONJ risk though these events were rare. PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42021236220).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Miller, P. D., Hattersley, G., Riis, B. J., Williams, G. C., Lau, E., Russo, L. A., Alexandersen, P., Zerbini, C. A. F., Hu, M.-Y., Harris, A. G., et al. (2016) · JAMA · doi:10.1001/jama.2016.11136 · Cited by 875
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft
Schilcher, J., Michaëlsson, K., & Aspenberg, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010650 · Cited by 695
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett-Bowie, S.-A. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61120-5 · Cited by 603
Kendler, D. L., Marin, F., Zerbini, C. A. F., Russo, L. A., Greenspan, S. L., Zikan, V., Bagur, A., Malouf-Sierra, J., Lakatos, P., Fahrleitner-Pammer, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32137-2 · Cited by 598
Delmas, P. D., Ensrud, K. E., Adachi, J. D., Harper, K. D., Sarkar, S., Gennari, C., Reginster, J., Pols, H. A. P., Recker, R. R., Harris, S. T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3609 · Cited by 563
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
HARDY, R. J., & THOMPSON, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6<619::aid-sim188>3.0.co;2-a · Cited by 522
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., Cauley, J., Leung, P. C., Boonen, S., Santora, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 512
Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508
Tsourdi, E., Langdahl, B., Cohen-Solal, M., Aubry-Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.003 · Cited by 504
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Park-Wyllie, L. Y. (2011) · JAMA · doi:10.1001/jama.2011.190 · Cited by 442
Incidence of atypical nontraumatic diaphyseal fractures of the femur
Dell, R. M., Adams, A. L., Greene, D. F., Funahashi, T. T., Silverman, S. L., Eisemon, E. O., Zhou, H., Burchette, R. J., & Ott, S. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1719 · Cited by 441
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates
Black, D. M., Geiger, E. J., Eastell, R., Vittinghoff, E., Li, B. H., Ryan, D. S., Dell, R. M., & Adams, A. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916525 · Cited by 407
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Wong, S., Wiessing, K. R., Bolland, M. J., Bastin, S., & Gamble, G. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808082 · Cited by 397
Abrahamsen, B., Eiken, P., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081247 · Cited by 366
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359
Papapoulos, S., Chapurlat, R., Libanati, C., Brandi, M. L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Man, Z., Mellström, D., Radominski, S. C., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1479 · Cited by 344
Barrionuevo, P., Kapoor, E., Asi, N., Alahdab, F., Mohammed, K., Benkhadra, K., Almasri, J., Farah, W., Sarigianni, M., Muthusamy, K., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00192 · Cited by 337
Jamal, S. A., Bauer, D. C., Ensrud, K. E., Cauley, J. A., Hochberg, M., Ishani, A., & Cummings, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070112 · Cited by 301
Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3234-7 · Cited by 274
Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018
Sarafrazi, N. (2021) · doi:10.15620/cdc:103477 · Cited by 273
Nakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3479 · Cited by 268
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
Bone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Mellström, D., Radominski, S. C., Reginster, J.-Y., Resch, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1597 · Cited by 254
Black, D. M., Reid, I. R., Cauley, J. A., Cosman, F., Leung, P. C., Lakatos, P., Lippuner, K., Cummings, S. R., Hue, T. F., Mukhopadhyay, A., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2442 · Cited by 253
Bisphosphonates for steroid-induced osteoporosis
Allen, C. S., Yeung, J. H., Vandermeer, B., & Homik, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001347.pub2 · Cited by 248
Siris, E. S., Harris, S. T., Eastell, R., Zanchetta, J. R., Goemaere, S., Diez-Perez, A., Stock, J. L., Song, J., Qu, Y., Kulkarni, P. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050509 · Cited by 243
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A., & Krege, J. H. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0189-8 · Cited by 235
Pharmacology of bisphosphonates
Cremers, S., Drake, M. T., Ebetino, F. H., Bilezikian, J. P., & Russell, R. G. G. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13867 · Cited by 223
Lewiecki, E. M., Dinavahi, R. V., Lazaretti-Castro, M., Ebeling, P. R., Adachi, J. D., Miyauchi, A., Gielen, E., Milmont, C. E., Libanati, C., & Grauer, A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3622 · Cited by 207
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Anastasilakis, A. D., Makras, P., Yavropoulou, M. P., Tabacco, G., Naciu, A. M., & Palermo, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010152 · Cited by 200
Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., & Psaty, B. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.826 · Cited by 199
Schilcher, J., Koeppen, V., Aspenberg, P., & Michaëlsson, K. (2015) · Acta Orthopaedica · doi:10.3109/17453674.2015.1004149 · Cited by 198
Boonen, S., Orwoll, E. S., Wenderoth, D., Stoner, K. J., Eusebio, R., & Delmas, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081214 · Cited by 193
Bisphosphonate Use and the Risk of Adverse Jaw Outcomes
Cartsos, V. M., Zhu, S., & Zavras, A. I. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0016 · Cited by 183
Sørensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D., Cummings, S. R., & Baron, J. A. (2008) · BMJ · doi:10.1136/bmj.39507.551644.be · Cited by 178
Cosman, F., Crittenden, D. B., Ferrari, S., Khan, A., Lane, N. E., Lippuner, K., Matsumoto, T., Milmont, C. E., Libanati, C., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3427 · Cited by 175
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4175 · Cited by 170
for the Bazedoxifene Study Group, Silverman, S. L., Chines, A. A., Kendler, D. L., Kung, A. W. C., Teglbjærg, C. S., Felsenberg, D., Mairon, N., Constantine, G. D., & Adachi, J. D. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1691-1 · Cited by 165
Anastasilakis, A. D., Papapoulos, S. E., Polyzos, S. A., Appelman-Dijkstra, N. M., & Makras, P. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3853 · Cited by 162
Abrahamsen, B., Eiken, P., & Eastell, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1571 · Cited by 160
McClung, M. R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H. G., Benhamou, C.-L., Lems, W. F., Minisola, S., Halse, J., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.536 · Cited by 158
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women
Greenspan, S. L., Perera, S., Ferchak, M. A., Nace, D. A., & Resnick, N. M. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0747 · Cited by 145
Wright, N. C., Saag, K. G., Dawson-Hughes, B. F., Khosla, S., & Siris, E. S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3865-3 · Cited by 138
Boonen, S., Black, D. M., Colon-Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., Mesenbrink, P. G., Haentjens, P., & Lyles, K. W. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02673.x · Cited by 136
Cosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 136
Boonen, S., Marín, F., Mellström, D., Xie, L., Desaiah, D., Krege, J. H., & Rosen, C. J. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00695.x · Cited by 134
Eriksen, E. F., Lyles, K. W., Colon-Emeric, C. S., Pieper, C. F., Magaziner, J. S., Adachi, J. D., Hyldstrup, L., Recknor, C. P., Nordsletten, L., Lavecchia, C., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090209 · Cited by 134
Grbic, J. T., Landesberg, R., Lin, S., Mesenbrink, P. G., Reid, I. R., Leung, P., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., et al. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0017 · Cited by 134
Cosman, F., Miller, P. D., Williams, G. C., Hattersley, G., Hu, M., Valter, I., Fitzpatrick, L. A., Riis, B. J., Christiansen, C., Bilezikian, J. P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.10.009 · Cited by 130
Ringe, J. D., Faber, H., & Dorst, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7988 · Cited by 127
The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid
Grbic, J. T., Black, D. M., Lyles, K. W., Reid, D. M., ORWOLL, E. S., McClung, M. R., Bucci-Rechtweg, C. M., & Su, G. (2010) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2010.0082 · Cited by 126
Eastell, R., Black, D. M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K., Cummings, S. R., Delmas, P. D., Palermo, L., Mesenbrink, P. G., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2765 · Cited by 118
Geusens, P., Marín, F., Kendler, D. L., Russo, L. A. T., Zerbini, C. A. F., Minisola, S., Body, J. J., Lespessailles, É., Greenspan, S. L., Bagur, A., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3384 · Cited by 116
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis
Lyu, H., Yoshida, K., Zhao, S. S., Wei, J., Zeng, C., Tedeschi, S. K., Leder, B. Z., Lei, G., Tang, P., & Solomon, D. H. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0882 · Cited by 115
Atrial fibrillation in fracture patients treated with oral bisphosphonates
Abrahamsen, B., Eiken, P., & Brixen, K. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02065.x · Cited by 114
Ringe, J. D., Dorst, A., Faber, H., & Ibach, K. (2004) · Rheumatology International · doi:10.1007/s00296-003-0388-y · Cited by 113
The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis
Byun, J.-H., Jang, S., Lee, S., Park, S., Yoon, H. K., Yoon, B., & Ha, Y. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.37 · Cited by 98
Palacios, S., Silverman, S. L., de Villiers, T. J., Levine, A. B., Goemaere, S., Brown, J. P., Nardone, F. D. C., Williams, R., Hines, T., Mirkin, S., et al. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000419 · Cited by 93
Cosman, F., Hattersley, G., Hu, M., Williams, G. C., Fitzpatrick, L. A., & Black, D. M. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2991 · Cited by 93
Broadwell, A., Chines, A. A., Ebeling, P. R., Franek, E., Huang, S., Smith, S., Kendler, D. L., Messina, O. D., & Miller, P. D. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa851 · Cited by 92
Kim, S. C., Schneeweiß, S., Katz, J. N., Levin, R., & Solomon, D. H. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.288 · Cited by 91
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Leder, B. Z. (2018) · JBMR Plus · doi:10.1002/jbm4.10041 · Cited by 91
Cosman, F., Crittenden, D. B., Ferrari, S., Lewiecki, E. M., Jaller-Raad, J. J., Zerbini, C. A. F., Milmont, C. E., Meisner, P. D., Libanati, C. R., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3439 · Cited by 82
Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3179-x · Cited by 78
Nakamura, T., Fukunaga, M., Nakano, T., Kishimoto, H., Ito, M., Hagino, H., Sone, T., Taguchi, A., Tanaka, S., Ohashi, M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3736-y · Cited by 78
Tennis, P. S., Rothman, K. J., Bohn, R. L., Tan, H., Zavras, A. I., Laskarides, C., Calingaert, B., & Anthony, M. S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3292 · Cited by 77
Morii, H., Ohashi, Y., Taketani, Y., Fukunaga, M., Nakamura, T., Itabashi, A., Sarkar, S., & Harper, K. D. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1424-1 · Cited by 75
Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation
Bunch, T. J., Anderson, J. L., May, H. T., Muhlestein, J. B., Horne, B. D., Crandall, B. G., Weiss, J. P., LAPPE, D. L., Osborn, J. S., & Day, J. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.037 · Cited by 73
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
Siris, E. S., Simon, J. A., Barton, I. P., McClung, M. R., & Grauer, A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0493-y · Cited by 72
Ringe, J. D., Farahmand, P., Schacht, E., & Rozehnal, A. (2007) · Rheumatology International · doi:10.1007/s00296-006-0288-z · Cited by 70
Once‐Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture
Boonen, S., ORWOLL, E. S., Magaziner, J. S., Colon-Emeric, C. S., Adachi, J. D., Bucci-Rechtweg, C. M., Haentjens, P., Kaufman, J., Rizzoli, R., Vanderschueren, D., et al. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03666.x · Cited by 69
Ferrari, S., Eastell, R., Napoli, N., Schwartz, A. V., Hofbauer, L. C., Chines, A. A., Wang, A., Pannacciulli, N., & Cummings, S. R. (2020) · Bone · doi:10.1016/j.bone.2020.115268 · Cited by 69
Prevrhal, S., Krege, J. H., Chen, P., Genant, H. K., & Black, D. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902790993 · Cited by 63
For the MOVER Study Group, Nakamura, T., Nakano, T., Ito, M., Hagino, H., Hashimoto, J., Tobinai, M., & Mizunuma, H. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9734-6 · Cited by 59
Miyauchi, A., Dinavahi, R. V., Crittenden, D. B., Yang, W., Maddox, J., Hamaya, E., Nakamura, Y., Libanati, C. R., Grauer, A., & Shimauchi, J. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0608-z · Cited by 59
Hagino, H., Sugimoto, T., Tanaka, S., Sasaki, K., Sone, T., Nakamura, T., Soen, S., & Mori, S. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05996-2 · Cited by 57
McCloskey, E. V., Johansson, H., Odén, A., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3163 · Cited by 51
Chiu, W., Chien, J., Yang, W., Juang, J. J., Lee, J., & Tsai, K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4119 · Cited by 49
FRAX and the effect of teriparatide on vertebral and non-vertebral fracture
Harvey, N. C., Kanis, J. A., Odén, A., Burge, R. T., Mitlak, B., Johansson, H., & McCloskey, E. V. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3173-3 · Cited by 46
Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis
Rhee, C. W., Lee, J.-S., Oh, S., Choi, N., & Park, B. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1608-z · Cited by 45
Kim, S. H., Lee, Y., Kim, T.-Y., Ha, Y., Jang, S., & Kim, H. Y. (2020) · Bone · doi:10.1016/j.bone.2020.115650 · Cited by 44
Osteoporosis treatment and atrial fibrillation
Huang, W.-F., Tsai, Y., Wen, Y., Hsiao, F., Kuo, K. N., & Tsai, C.-R. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181b34749 · Cited by 43
Hsiao, F., Huang, W.-F., Chen, Y., Wen, Y., Kao, Y.-H., Chen, L., & Tsai, Y. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.006 · Cited by 42
Geusens, P., Oates, M. K., Miyauchi, A., Adachi, J. D., Lazaretti‐Castro, M., Ebeling, P. R., Niño, C. A. P., Milmont, C. E., Grauer, A., & Libanati, C. R. (2019) · JBMR Plus · doi:10.1002/jbm4.10211 · Cited by 41
Zhou, J., Liu, B., Qin, M., & Liu, J. (2020) · Orthopaedic Surgery · doi:10.1111/os.12701 · Cited by 41
McClung, M. R., Harvey, N. C., Fitzpatrick, L. A., Miller, P. D., Hattersley, G., Wang, Y., & Cosman, F. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001080 · Cited by 40
Chiu, W., Yang, W., Chien, J., Lee, J., & Tsai, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196419 · Cited by 40
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX
Harvey, N. C., Kanis, J. A., Odén, A., Nakamura, T., Shiraki, M., Sugimoto, T., Kuroda, T., Johansson, H., & McCloskey, E. V. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3129-7 · Cited by 39
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
Kim, Y.-S., Tian, Y., Yang, J., Huser, V., Jin, P., Lambert, C. G., Park, H., You, S. C., Park, R. W., Rijnbeek, P. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68037-8 · Cited by 39
on behalf of the Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group, Lapi, F., Cipriani, F., Caputi, A. P., Corrao, G., Vaccheri, A., Sturkenboom, M., Bari, M. D., Gregori, D., Carle, F., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2013-y · Cited by 36
Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis
Krege, J. H., & Wan, X. (2011) · Bone · doi:10.1016/j.bone.2011.10.018 · Cited by 34
Rodríguez, A. J., Ernst, M., Nybo, M., Prieto‐Alhambra, D., Ebeling, P. R., Hermann, A. P., & Abrahamsen, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa481 · Cited by 34
Kwon, J., Park, E.-J., Jung, S., Sohn, H. S., Ryu, H. M., & Suh, H. S. (2015) · Journal of Dental Research · doi:10.1177/0022034515587862 · Cited by 33
Prieto‐Alhambra, D., Judge, A., Arden, N. K., Cooper, C. C., Lyles, K. W., & Javaid, M. K. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2420-8 · Cited by 33
Lau, E. M. C., Dinavahi, R. V., Woo, Y. C., Wu, C., Guan, J., Maddox, J., Tolman, C., Yang, W., & Shin, C. S. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05324-0 · Cited by 32
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis
Hwang, J., Chin, L.-S., Chen, J., Yang, T., Chen, P.-Q., Tsai, K., & Leung, P. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0223-y · Cited by 31
Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women
Bai, H., Jing, D., Guo, A., & Yin, S. (2013) · Journal of International Medical Research · doi:10.1177/0300060513480917 · Cited by 31
Fujita, T., Fukunaga, M., Itabashi, A., Tsutani, K., & Nakamura, T. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9777-8 · Cited by 30
Lu, P.-Y., Hsieh, C.-F., Tsai, Y., & Huang, W.-F. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.012 · Cited by 30
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Wiessing, K. R., Bolland, M. J., Bastin, S., & Gamble, G. D. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12901 · Cited by 29
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis
Nakamura, T., Liu, J. L., Morii, H., Huang, Q., Zhu, H. M., Qu, Y., Hamaya, E., & Thiébaud, D. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0702-3 · Cited by 28
Osteonecrosis of the Jaw in Older Osteoporosis Patients Treated with Intravenous Bisphosphonates
Baillargeon, J., Kuo, Y. F., Lin, Y., Wilkinson, G. S., & Goodwin, J. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q239 · Cited by 28
Nakano, T., Shiraki, M., Sugimoto, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Kuroda, T., & Nakamura, T. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0505-2 · Cited by 27
McCloskey, E. V., Fitzpatrick, L. A., Hu, M.-Y. Y., Williams, G. C., & Kanis, J. A. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0564-7 · Cited by 27
Body, J., Marín, F., Kendler, D. L., Zerbini, C. A. F., López‐Romero, P., Moericke, R., Casado, E., Fahrleitner‐Pammer, A., Stepan, J. J., Lespessailles, É., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05463-4 · Cited by 27
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Palacios, S., Kalouche-Khalil, L., Rizzoli, R., Zapalowski, C., Resch, H., Adachi, J. D., Gallagher, J. C., Feldman, R. G., Kendler, D. L., Wang, A., et al. (2015) · Climacteric · doi:10.3109/13697137.2015.1045484 · Cited by 26
Bilezikian, J. P., Lin, C. J. F., Brown, J. P., Wang, A. T., Yin, X., Ebeling, P. R., Fahrleitner‐Pammer, A., Franek, E., Gilchrist, N. L., Miller, P. D., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05020-8 · Cited by 25
D’Silva, K. M., CROMER, S. J., Yu, E. W.-Y., Fischer, M. A., & Kim, S. C. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4174 · Cited by 25
Herrera, L., Leal, I., Lapi, F., Schuemie, M. J., Arcoraci, V., Cipriani, F., Sessa, E., Vaccheri, A., Piccinni, C. P., Staniscia, T., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-014-3020-y · Cited by 24
Lü, K., Yin, Y., Li, C., Jin, Y., & Shan, H.-Q. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05816-z · Cited by 24
Wotton, C. J., Green, J., Brown, A., Armstrong, M. E. G., Floud, S., Beral, V., & REEVES, G. K. (2019) · Bone · doi:10.1016/j.bone.2019.04.003 · Cited by 23
Geusens, P., Feldman, R., Oates, M. K., Thomas, T., Makras, P., Jakob, F. J., Langdahl, B. L., Wang, Z., Rojeski, M., & Libanati, C. R. (2021) · Bone · doi:10.1016/j.bone.2021.116209 · Cited by 22
Hagino, H., Yoshida, S., Hashimoto, J., Matsunaga, M., Tobinai, M., & Nakamura, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9927-7 · Cited by 21
Boonen, S., Eastell, R., Su, G., Mesenbrink, P. G., Cosman, F., Cauley, J. A., Reid, I. R., Claessens, F., Vanderschueren, D., Lyles, K. W., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1605 · Cited by 21
Tanaka, S., Kuroda, T., Sugimoto, T., Nakamura, T., & Shiraki, M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.879440 · Cited by 18
Kendler, D. L., Marín, F., Geusens, P., López‐Romero, P., Lespessailles, É., Body, J.-J., & Minisola, S. (2019) · Bone · doi:10.1016/j.bone.2019.115113 · Cited by 18
Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years
Lo, J. C.-M., Neugebauer, R. S., Ettinger, B. B., Chandra, M., Hui, R. L., Ott, S. M., Grimsrud, C. D., & Izano, M. A. (2020) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-020-03672-w · Cited by 18
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
McClung, M. R., Williams, G. C., Hattersley, G., Fitzpatrick, L. A., Wang, Y., & Miller, P. D. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0375-z · Cited by 16
Benefits and risks of raloxifene by vertebral fracture status
Sontag, A., Wan, X., & Krege, J. H. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903427082 · Cited by 15
Ito, M., Tobinai, M., Yoshida, S., Hashimoto, J., & Nakamura, T. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0723-x · Cited by 15
Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
Jung, S.-M., Han, S., & Kwon, H.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00796 · Cited by 15
Saag, K. G., Williams, S. A., Wang, Y., Weiss, R. J., & Cauley, J. A. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.04.012 · Cited by 15
Kirchmayer, U., Sorge, C., Sultana, J., Lapi, F., Onder, G., Agabiti, N., Cascini, S., Roberto, G., Corrao, G., Vitale, C., et al. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619838138 · Cited by 14
Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
Sugimoto, T., Matsumoto, T., Hosoi, T., Shiraki, M., Kobayashi, M., Okubo, N., Takami, H., & Nakamura, T. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01119-9 · Cited by 14
Relationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter
Thadani, S. R., Ristow, B., Blackwell, T., Mehra, R., Stone, K. L., Marcus, G. M., Varosy, P. D., Cummings, S. R., & Cawthon, P. M. (2015) · CHEST Journal · doi:10.1016/j.chest.2015.11.022 · Cited by 11
Yang, H., Huang, J.-H., Chiu, H., et al. (2018) · Medicine · doi:10.1097/md.0000000000012947 · Cited by 10
Park, C., Lim, S., Moon, Y., Choi, S.-H., Shin, M., Min, Y., Yoon, B.-K., & Park, Y.-S. (2021) · Climacteric · doi:10.1080/13697137.2021.1915271 · Cited by 10
Efficacy and safety of bazedoxifene in postmenopausal Latino women with osteoporosis
Bueno, J. A. H., Arias, L., Yu, C., Williams, R., & Komm, B. S. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000889 · Cited by 8
Cited by
MiR-30 family: a novel avenue for treating bone and joint diseases?
Huang, J., Li, Y., Zhu, S., Wang, L., Yang, L., & He, C. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.81990 · Cited by 23
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“Long-term use of BPs could excessively inhibit bone remodeling, leading to atypical fractures and osteonecrosis of the jaw [48 – 50].”
Background
Metadata
- Authors
- Ayers, C., Kansagara, D., Lazur, B., Fu, R., Kwon, A., & Harrod, C.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2023-02
- Volume
- 176
- Issue
- 2
- Pages
- 182-195
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4313455245
- Cited by
- 282
- References
- 148
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.